Byondis B.V.: Byondis Initiates Phase I Study of Next Genera

BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/ --

Related Keywords

Italy , Netherlands , Nijmegen , Gelderland , Belgium , Dutch , Prnewswire Byondis , Kostenloser Wertpapierhandel , Wim Dokter , Jan Schellens , Us Food Drug Administration , European Medicines Agency , Conjugation Technology , Widely Overexpressed , Uses Proprietary Technologies Designed , Enhance Efficacy , Human Dose Escalation , Expansion Trial With , Antibody Drug Conjugate , Expressing Locally Advanced , Metastatic Solid , Byondis Chief Medical Officer Jan Schellens , Byondis Chief Scientific Officer Wim Dokter , Biologics License Application , Drug Administration , Marketing Authorization Application , Dose Escalation , Maximum Tolerated Dose , Recommended Dose , Next Generation Antibody Drug , Proprietary Linker Drug , Site Specific Conjugation , Good Manufacturing Practice , Byondis , Nitiates , Hase , Study , Text , Generation , Ntibody , Drug , Conjugate , Yon3521 ,